Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer.

[1]  P. Loadman,et al.  Immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: Relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy , 2004, International journal of cancer.

[2]  P. Hoskin,et al.  GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON , 2003, British Journal of Cancer.

[3]  A. Harris,et al.  GLUT‐1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: Relationship to pimonidazole binding , 2003, International journal of cancer.

[4]  M. Bibby,et al.  Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9 , 2002, British journal of pharmacology.

[5]  James B. Mitchell,et al.  Nitroxides as antioxidants: Tempol protects against EO9 cytotoxicity. , 2002 .

[6]  A. P. M. Meijden.  The use of the marker tumor concept in Ta, T1 bladder cancer , 2002 .

[7]  J. Brown,et al.  A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9 , 2001, British Journal of Cancer.

[8]  A. Harris,et al.  The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions. , 2000, Biochemical pharmacology.

[9]  P. Loadman,et al.  Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. , 1998, British Journal of Cancer.

[10]  A. te Velde,et al.  EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. , 1996, European journal of cancer.

[11]  A. te Velde,et al.  A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG). , 1996, Annals of Oncology.

[12]  M. Grever,et al.  Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. , 1996, Journal of the National Cancer Institute.

[13]  P. Workman,et al.  DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9. , 1994, British Journal of Cancer.

[14]  J. Verweij,et al.  Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09. , 1994, Journal of the National Cancer Institute.

[15]  G. Adams,et al.  Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia. , 1994, European Journal of Cancer.

[16]  M. Krishna,et al.  Nitroxides as antioxidants. , 1994, Methods in enzymology.

[17]  P. Workman,et al.  Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. , 1994, Oncology research.

[18]  J. Double,et al.  EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. , 1993, European journal of cancer.

[19]  J. Double,et al.  Factors affecting the in vitro dissolution of cobalt oxide. , 1992, British Journal of Cancer.